Sage Therapeutics EBIT

Sage Therapeutics (SAGE) currently reports a EBIT of $-300M as of June 2025. That compares with $-420M in the prior-year period — up 27.1% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Sage Therapeutics's EBIT history and peer comparisons.

Sage Therapeutics's EBIT increased from $-420M to $-300M — a 27.1% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sage Therapeutics's EBIT of $-300M is lower than the Healthcare sector average of $23B. That is roughly 101.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sage Therapeutics reported $-300M in EBIT as of June 2025. That compares with $-420M in the prior-year period — up 27.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-300M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Sage Therapeutics, and consider following SAGE for alerts when major investors trade the stock.